REGN - Regeneron Pharmaceuticals Inc. (REGN) Q4 2023 Earnings Call Transcript
2024-02-02 11:59:04 ET
Regeneron Pharmaceuticals, Inc. (REGN)
Q4 2023 Earnings Conference Call
February 2, 2024 8:30 AM ET
Company Participants
Ryan Crowe - Senior Vice President, Investor Relations
Leonard Schleifer - President and Chief Executive Officer
George Yancopoulos - Co-Chair, Co-Founder, President and Chief Scientific Officer
Marion McCourt - Executive Vice President and Head of Commercial
Bob Landry - Executive Vice President and Chief Financial Officer
Conference Call Participants
Tyler Van Buren - TD Cowen
Brian Abrahams - RBC Capital Markets
Mohit Bansal - Wells Fargo
Christopher Raymond - Piper Sandler
Colin Bristow - UBS
Evan Seigerman - BMO Capital Markets
Salveen Richter - Goldman Sachs
David Risinger - Leerink Partners
Carter Gould - Barclays
Presentation
Operator
Welcome to the Regeneron Pharmaceuticals Fourth Quarter 2023 Earnings Conference Call. My name is Shannon and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session. Please note that this conference is being recorded.
I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin.
Ryan Crowe
Thank you, Shannon. Good morning, good afternoon, and good evening to everyone listening around the world. Thank you for your interest in Regeneron, and welcome to our fourth quarter 2023 earnings conference call. An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after the call ends.
Joining me today are Dr. Leonard Schleifer, Co-Chair, Co-Founder, President and Chief Executive Officer; Dr. George Yancopoulos, Co-Chair, Co-Founder, President and Chief Scientific Officer; Marion McCourt, Executive Vice President and Head of Commercial; Bob Landry, Executive Vice President and Chief Financial Officer; and Chris Fenimore, Senior Vice-President and Controller.
As many of you already know. Bob will retire from Regeneron, after our Form 10-K as filed next week, and Chris has been appointed to become Regeneron's next CFO upon Bob's retirement. After our prepared remarks the remaining time will be available for your questions. We anticipate today's call will last approximately 60 minutes.
I'd like to remind you that remarks made on today's call may include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and business, financial forecast and guidance, development programs and related anticipated milestones, collaborations, finances, regulatory matters, payer coverage and reimbursement issues, intellectual property, pending litigation and other proceedings and competition....
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2023 Earnings Call Transcript